Genara Limson

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.6K citations

As04-adjuvanted Vaccine, Gynecology, Oncogenic Hpv Types +16

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

Jorma Paavonen, David Jenkins, F. Xavier Bosch et al. · The Lancet · 2007 · 1.3K citations

Vaccination, Vaccine Safety, Interim Analysis +9

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler et al. · The Lancet Oncology · 2011 · 693 citations

Vaccination, Cervical Cancer Screening, Hpv-16/18 As04-adjuvanted Vaccine +14

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland et al. · The Lancet Oncology · 2011 · 499 citations

Vaccination, Vaccine Safety, Cervical Cancer Screening +14

Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV‐16/18

Anne Szarewski, W.A.J. Poppe, S. Rachel Skinner et al. · International Journal of Cancer · 2011 · 138 citations · Full text

Previous Exposure, Gynecology, Cervical Cancer Prevention +23